iZafe Group AB Series B

ST:IZAFE-B Sweden Medical Instruments & Supplies
Market Cap
$12.87 Million
Skr144.39 Million SEK
Market Cap Rank
#27515 Global
#371 in Sweden
Share Price
Skr0.40
Change (1 day)
-1.00%
52-Week Range
Skr0.24 - Skr0.72
All Time High
Skr16.60
Categories
Companies in Sweden Medical Instruments & Supplies
About

iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses. It also o… Read more

iZafe Group AB Series B (IZAFE-B) - Net Assets

Latest net assets as of September 2025: Skr16.49 Million SEK

Based on the latest financial reports, iZafe Group AB Series B (IZAFE-B) has net assets worth Skr16.49 Million SEK as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr40.20 Million) and total liabilities (Skr23.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr16.49 Million
% of Total Assets 41.02%
Annual Growth Rate 6.43%
5-Year Change -66.98%
10-Year Change 11.51%
Growth Volatility 152.28

iZafe Group AB Series B - Net Assets Trend (2010–2024)

This chart illustrates how iZafe Group AB Series B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for iZafe Group AB Series B (2010–2024)

The table below shows the annual net assets of iZafe Group AB Series B from 2010 to 2024.

Year Net Assets Change
2024-12-31 Skr9.73 Million -61.63%
2023-12-31 Skr25.35 Million -34.93%
2022-12-31 Skr38.96 Million -4.35%
2021-12-31 Skr40.73 Million +38.27%
2020-12-31 Skr29.46 Million -20.15%
2019-12-31 Skr36.89 Million +264.66%
2018-12-31 Skr10.12 Million -9.56%
2017-12-31 Skr11.19 Million +106.52%
2016-12-31 Skr5.42 Million -37.91%
2015-12-31 Skr8.72 Million -3.52%
2014-12-31 Skr9.04 Million -22.64%
2013-12-31 Skr11.69 Million -38.21%
2012-12-31 Skr18.92 Million +513.75%
2011-12-31 Skr3.08 Million -24.15%
2010-12-31 Skr4.06 Million --

Equity Component Analysis

This analysis shows how different components contribute to iZafe Group AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 16561977900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock Skr55.12 Million 566.58%
Other Components Skr130.87 Million 1345.26%
Total Equity Skr9.73 Million 100.00%

iZafe Group AB Series B Competitors by Market Cap

The table below lists competitors of iZafe Group AB Series B ranked by their market capitalization.

Company Market Cap
Healthconn Corp.
TWO:6665
 		$12.58 Million
Asia Precision Public Company Limited
BK:APCS
 		$12.58 Million
Thai Rubber Latex Group Public Company Limited
BK:TRUBB
 		$12.58 Million
Laredo Oil Inc
PINK:LRDC
 		$12.59 Million
AlzeCure Pharma
ST:ALZCUR
 		$12.56 Million
Rocky Mountain Chocolate Factory
NASDAQ:RMCF
 		$12.56 Million
Wellysun Inc
TW:6988
 		$12.56 Million
Radhika Jeweltech Limited
NSE:RADHIKAJWE
 		$12.55 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in iZafe Group AB Series B's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 25,353,000 to 9,728,000, a change of -15,625,000 (-61.6%).
  • Net loss of 20,509,000 reduced equity.
  • Share repurchases of 4,884,000 reduced equity.
  • New share issuances of 88,000 increased equity.
  • Other factors increased equity by 9,680,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Skr-20.51 Million -210.82%
Share Repurchases Skr4.88 Million -50.21%
Share Issuances Skr88.00K +0.9%
Other Changes Skr9.68 Million +99.51%
Total Change Skr- -61.63%

Book Value vs Market Value Analysis

This analysis compares iZafe Group AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 11.22x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.54x to 11.22x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2010-12-31 Skr0.73 Skr0.40 x
2011-12-31 Skr0.46 Skr0.40 x
2012-12-31 Skr2.36 Skr0.40 x
2013-12-31 Skr1.42 Skr0.40 x
2014-12-31 Skr1.10 Skr0.40 x
2015-12-31 Skr0.93 Skr0.40 x
2016-12-31 Skr0.47 Skr0.40 x
2017-12-31 Skr0.92 Skr0.40 x
2018-12-31 Skr0.47 Skr0.40 x
2019-12-31 Skr1.72 Skr0.40 x
2020-12-31 Skr0.84 Skr0.40 x
2021-12-31 Skr0.88 Skr0.40 x
2022-12-31 Skr0.49 Skr0.40 x
2023-12-31 Skr0.11 Skr0.40 x
2024-12-31 Skr0.04 Skr0.40 x

Capital Efficiency Dashboard

This dashboard shows how efficiently iZafe Group AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -210.82%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -257.85%
  • • Asset Turnover: 0.33x
  • • Equity Multiplier: 2.49x
  • Recent ROE (-210.82%) is below the historical average (-87.22%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2010 -145.36% -157526.53% 0.00x 1.20x Skr-6.31 Million
2011 -160.33% -18704.64% 0.01x 1.15x Skr-5.25 Million
2012 -15.42% -7462.56% 0.00x 1.27x Skr-4.81 Million
2013 -61.85% -126867.08% 0.00x 1.46x Skr-8.40 Million
2014 -35.07% 0.00% 0.00x 1.67x Skr-4.08 Million
2015 -29.76% 0.00% 0.00x 1.42x Skr-3.47 Million
2016 -117.33% 0.00% 0.00x 1.49x Skr-6.90 Million
2017 -38.16% -2754.19% 0.01x 1.23x Skr-5.39 Million
2018 -111.81% -149.41% 0.17x 4.31x Skr-12.32 Million
2019 -62.66% -161.33% 0.20x 1.94x Skr-26.81 Million
2020 -43.30% -143.24% 0.25x 1.19x Skr-15.70 Million
2021 -89.06% -8207.01% 0.01x 1.19x Skr-40.35 Million
2022 -60.38% -3227.16% 0.01x 1.30x Skr-27.42 Million
2023 -126.91% -1765.92% 0.05x 1.37x Skr-34.71 Million
2024 -210.82% -257.85% 0.33x 2.49x Skr-21.48 Million

Industry Comparison

This section compares iZafe Group AB Series B's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

  • Industry: Medical Instruments & Supplies
  • Average net assets among peers: $203,717,301
  • Average return on equity (ROE) among peers: -18.91%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
iZafe Group AB Series B (IZAFE-B) Skr16.49 Million -145.36% 1.44x $12.58 Million
AddLife AB (publ) (ALIF-B) $1.89 Billion 27.39% 1.20x $1.42 Billion
Biotage AB (BIOT) $476.77 Million 8.68% 0.24x $787.18 Million
Bonesupport Holding AB (BONEX) $124.31 Million -129.56% 0.58x $897.79 Million
Dynavox Group (DYVOX) $210.60 Million 23.08% 5.28x $786.85 Million
Ortivus AB ser. A (ORTI-A) $84.63 Million -21.84% 0.94x $1.20 Million
S2Medical AB (S2M) $25.11 Million -73.41% 0.22x $641.00K
Stille AB (STIL) $189.81 Million 14.40% 0.80x $82.32 Million
Synsam AB (SYNSAM) $-1.37 Billion 0.00% 0.00x $731.69 Million